Impact of age at appendectomy on development of type 2 diabetes: A population-based cohort study

Yang-Ming Lee¹,2, Chew-Teng Kor², Diko Zhou³, Hsueh-Chou Lai⁴, Chia-Chu Chang²,5*, Wen-Lung Ma¹,3,4*

¹ Graduate Institution of Clinical Medical Science, and Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, ² Internal Medicine Research Center, Changhua Christian Hospital, Changhua, Taiwan, ³ BioActive Lipid Research Center (BALRC), Department of Surgery, BenQ Medical Center, Suzhou, Jiangsu Province, China, ⁴ Sex Hormone Research Center, and Department of Gastroenterology, China Medical University Hospital, Taichung, Taiwan, ⁵ School of Medicine, Chung Shan Medical University, Taichung, Taiwan

* maverick@mail.cmu.edu.tw (WLM); 27509@cch.org.tw (CCC)

Abstract

Aim

Diabetes is a complex metabolic disease characterized by chronic low-grade inflammation in which genetic and environmental factors are involved. Growing evidence implicates that alterations of the gut microbiota potentially contribute to the emergence of metabolic diseases. The human appendix has more recently been recognized as a microbial reservoir for repopulating the gastrointestinal tract and an important part of the immune system. Thus, appendectomy may influence microbial ecology and immune function. This study investigated the association between appendectomy and type 2 diabetes risk.

Methods

We analyzed a cohort of 10954 patients who underwent appendectomy between 1998 and 2013 based on the Taiwan National Health Insurance Program database. A comparison cohort of 43815 persons without appendectomy was selected randomly and matched by sex, age, comorbidities, and index year. To ensure reliability of the results, a sensitivity analysis using a propensity score–matched study was performed. We observed the subsequent development of type 2 diabetes in both cohorts.

Results

Although the overall incidence of type 2 diabetes in the appendectomy patients was 7.9% higher than that in the non-appendectomy patients, it was not statistically significant (95% confidence interval [CI], 0.997–1.168) after the adjustment of confounding factors. Multivariate regression analysis revealed that the adjusted hazard ratio (HR) of type 2 diabetes was 1.347 for appendectomy patients < 30 years of age (95% CI, 1.009–1.798) compared to non-appendectomy patients. The incidence of type 2 diabetes was higher within 3 years of post-appendectomy follow-up than for non-appendectomy patients (HR, 2.017; 95% CI, 0.990–4.148).
Age impacted the association between appendectomy and type 2 diabetes risk ($P_{\text{interaction}} = 0.002$); in contrast, sex did not affect the association between appendectomy and type 2 diabetes risk ($P_{\text{interaction}} = 0.88$).

Conclusions
Our study results suggest that appendectomy increases type 2 diabetes risk, particularly when performed prior to middle age.

Introduction
Diabetes is one of the most serious public health issues worldwide due to its rapidly increasing incidence and tremendous amount of various vascular complications. According to the International Diabetes Federation, in 2015, the 415 million individuals had diabetes, a figure that is estimated to increase to 642 million by 2040 [1]. Diabetes is a complicated metabolic disease characterized by chronic inflammation [2, 3] that involves genetic and environmental factors. Insulin resistance, the core defect of metabolic diseases, is linked to low-grade inflammation; however, its detailed molecular mechanism remains to be determined. Recent studies have suggested that the gut microbiota play a fundamental role in metabolic disease development by modifying energy homeostasis [4–8]. Studies from animal models have shown that alterations in the gut microbiota contribute to the development of metabolic diseases by increasing endotoxemia-induced inflammation [9]. Furthermore, Cox et al. demonstrated that altering the intestinal microbiota in early life using low-dose penicillin switched the metabolic phenotype [10]. Ridaura et al. demonstrated that the microbiota derived from discordant obese twins affected murine metabolism [11].

Despite long being considered an evolutionary vestigial organ, the human appendix has more recently been recognized as an important part of the immune system. Furthermore, the human appendix may function as a “safe house” to preserve and protect commensal bacteria in the gastrointestinal tract via immune-mediated biofilm formation [12–15]. Consequently, appendectomy may change the gut microbiota composition and immune function, subsequently promoting the emergence of various inflammatory diseases, including colon cancer, Crohn’s disease, and rheumatoid arthritis [16–21]. This study aimed to investigate whether appendectomy increases the risk of type 2 diabetes (DM).

Informed consent statement. Although written informed consent was not provided by the participants for the use of their medical records in this study, the patient records were de-identified and anonymized prior to the investigation. The work was approved after a full ethical review by the Institutional Review Board (IRB) of the Changhua Christian Hospital (approval number 171210), and the IRB waived the need for consent.

Material and methods
Study population
We used a one-million-person random sample from people enrolled in the Taiwan National Health Insurance Program (NHIP). Started in 1995, the program includes 99% of the 23-million-plus people who live in Taiwan. This database from the NHIP is managed and established for investigators. With the hospitalization database from the Taiwan NIHP, the appendectomy group was determined as patients aged 20–84 years undergoing appendectomy from 1998 to
2013 (the International Classification of Diseases [ICD] 9th Revision, ICD-9 procedure codes 47.0 and 47.1). We identified a study group of 15917 patients who underwent appendectomy between 1998 and 2013. We excluded 2975 persons aged <18 or >100 years, 1538 persons with a history of DM history before the index date, 201 patients with any antidiabetic agent history before the index date, eight patients who underwent bariatric surgery, and 241 patients who did not survive or were followed up for <30 days. The remaining 10954 patients were included in the study as the appendectomy group. The index year was determined as the year the appendectomy was performed. We established a random frequency-matched study cohort for assessing the association between appendectomy and DM. For each identified appendectomy patient, four control groups were frequency matched by age, sex, and index year. A total of 10954 appendectomy patients and 43815 controls were included in the study cohort (Fig 1). We also performed a propensity score-matched sensitivity analysis to ensure the reliability of our results. Propensity scores were calculated using multivariate logistic regression to predict the probability of DM occurrence to balance the covariate distribution in the appendectomy and control groups. Based on the propensity score, 1:4 propensity score matching was performed in the sensitivity analysis.

All comorbidities were diagnosed with ICD-9 codes. The following comorbidities potentially related to DM included: hypertension (ICD-9 401–405), hyperlipidemia (ICD-9 272), gout (ICD-9 274), polycystic ovaries (ICD-9 256.4), cerebrovascular disease (ICD-9 430–438), renal disease (ICD-9 580–589), ischemic heart disease (CAD; ICD-9 410–414), chronic obstructive pulmonary disease (COPD; ICD-9 416.8, 416.9, 490–505, 506.4, 508.1, and 508), gestational diabetes (GDM) (ICD-9 648.0, 648.8), depression (ICD-9 296.2, 296.3, 300.4, and 311), obesity (ICD-9 278, 783.1, and V77.8), chronic pancreatitis (ICD-9 577.1), hepatitis B infection (HBV; ICD-9 070.20, 070.21, 070.22, 070.23, 070.30, 070.31, 070.32, 070.33, and V02.61), and hepatitis C infection (HCV; ICD-9 070.41, 070.44, 070.51, 070.54, 070.7, and V02.62).

The major outcome was a new diagnosis of DM (ICD-9 250.0–250.9) based on at least three outpatient diagnoses or one hospital discharge diagnosis during the follow-up period. All study subjects were followed until they were diagnosed with DM at the end of 2013.

Fig 1. Flow chart of the study subjects illustrating how we analyzed a cohort of 10954 patients who underwent appendectomy between 1998 and 2013 based on Taiwan National Health Insurance Program data. A comparison cohort of 43815 persons without appendectomy was randomly selected and frequency matched by sex, age, comorbidities, and index year. We observed the subsequent development of diabetes in both cohorts.

https://doi.org/10.1371/journal.pone.0205502.g001
Statistics

Demographic and clinical characteristics in the appendectomy and non-appendectomy subjects were presented as proportions and mean ± standard deviation (SD). The standardized differences were used with an absolute value for the standardized difference of >0.1 considered to indicate important imbalances between the two groups for categorical or continuous matching variables, respectively. The incidence of DM was measured as the event number of DM diagnosed during the follow-up year divided by the total follow-up person-years for each subject.

The Cox proportional hazards regression model was applied to measure the hazard ratio (HR) and 95% confidence interval (CI) for the risk of DM in the appendectomy compared to non-appendectomy groups. Multivariate Cox analysis with cause-specific hazard models was used to estimate adjusted hazard ratios (aHRs) adjusted for confounders for appendectomy and other comorbidities including hypertension, hyperlipidemia, gout, polycystic ovaries, depression, cerebrovascular disease, renal disease, CAD, COPD, GDM, obesity, chronic pancreatitis, HBV infection, HCV infection, medications (statins, atypical antipsychotics, HIV drug and corticosteroids for systemic immunosuppressants) and number of visiting clinics.

Uni- and multivariate survival analyses were performed for the incidence and relative risk of DM. A subgroup analysis was used to distinguish between DM risks in the appendectomy and non-appendectomy groups. We then used propensity score-matched analysis to assess the reliability of our results. Propensity scores were calculated using multivariate logistic regression to predict the probability of DM occurrence. The cumulative incidence curves from cause-specific hazard methods for the appendectomy and control groups were also analyzed.

Results

Of the 15917 patients in the appendectomy group, 10954 patients remained after the exclusion of 2975 patients <18 or >100 years of age, 1538 patients with a history of DM, 201 patients with a prescription history of antidiabetic agents, eight patients who underwent bariatric surgery, and 241 patients who did not survive or completed <30 days of follow-up. There were a total of 43815 persons in the control group.

Comparisons in demographic characteristics are shown in Table 1. The mean ages of the appendectomy and control groups were similar (39.5 years), and each was predominantly composed of males (51.06%). In cohort 1 (random frequency-matched analysis), the appendectomy and control groups were matched by hypertension, hyperlipidemia, gout, polycystic ovaries, depression, GDM, obesity, chronic pancreatitis, HBV and HCV, statins, atypical antipsychotics, HIV drugs, corticosteroids, and immunosuppressants. There was a slight difference in Charlson Comorbidity Index score and number of visiting clinics between the two appendectomy and control groups in cohort 1.

To assess the reliability of cohort 1, a propensity score-matched sensitivity analysis (cohort 2) was conducted, and it showed that the appendectomy and control groups had equal distributions of all demographic characteristics. Overall, 7.4% (n = 811) of patients with appendectomy developed type 2 DM versus 6.91% (n = 3027) of persons without appendectomy in cohort 1. Similar results were shown in cohort 2. Using this data mining strategy, we were able to examine the correlation between appendectomy and the development of type 2 DM. As shown in Table 2, we found the overall incidence of type 2 DM in the appendectomy patients was 7.9% higher than that in the control group, although the difference was not statistically significant (P = 0.06). The incidence of type 2 DM in the appendectomy patients < 30 years of age was 1.453-fold greater than that in the control group (95% CI, 1.093–1.933). The multivariable regression analysis revealed that the adjusted HR of type 2 DM was 1.347 for the appendectomy patients < 30 years (95% CI, 1.009–1.798) compared to controls. Age affected the
The association between appendectomy and type 2 DM ($P_{\text{interaction}} = 0.002$), whereas sex did not ($P_{\text{interaction}} = 0.88$).

Table 1. Comparisons in demographic characteristics, comorbidities medications and clinical outcomes in subjects with and without appendectomy.

|                      | Nonappendectomy | Appendectomy | Std* | Nonappendectomy | Appendectomy | Std* |
|----------------------|-----------------|--------------|------|-----------------|--------------|------|
| Sample size          | 43815           | 10954        | 0.000| 43815           | 10954        | 0.009|
| Gender               |                 |              |      |                 |              |      |
| F                    | 21443(48.94%)   | 5361(48.94%) | 0.000| 21252(48.5%)    | 5361(48.94%) | 0.009|
| M                    | 22372(51.06%)   | 5593(51.06%) | 0.000| 22564(51.5%)    | 5593(51.06%) | 0.009|
| Age stratified       |                 |              |      |                 |              |      |
| <20                  | 2270(5.18%)     | 635(5.8%)    | 0.027| 2596(5.92%)     | 635(5.8%)    | 0.005|
| 20–39                | 22216(50.7%)    | 5528(50.47%) | 0.005| 22438(51.21%)   | 5528(50.47%) | 0.014|
| 40–59                | 13818(31.54%)   | 3401(31.05%) | 0.011| 13644(31.14%)   | 3401(31.05%) | 0.002|
| 60–79                | 4896(11.17%)    | 1233(11.26%) | 0.003| 4537(10.35%)    | 1233(11.26%) | 0.029|
| > = 80              | 615(1.4%)       | 157(1.43%)   | 0.003| 601(1.37%)      | 157(1.43%)   | 0.005|
| Age, years           | 39.5±15.7       | 39.5±15.76   | 0.005| 39.08±15.55     | 39.5±15.76   | 0.038|
| Monthly income, NTD  |                 |              |      |                 |              |      |
| <15840               | 19924(45.47%)   | 5182(47.31%) | 0.037| 20719(47.29%)   | 5182(47.31%) | 0.000|
| 15840–25000          | 13792(31.48%)   | 3561(32.51%) | 0.022| 14107(32.2%)    | 3561(32.51%) | 0.007|
| ≥25000              | 10099(23.05%)   | 2211(20.18%) | 0.070| 8990(20.52%)    | 2211(20.18%) | 0.008|
| Number of visiting clinic | 15.24±13.75   | 16.97±14.85 | 0.165| 16.85±14.78     | 16.97±14.85 | 0.012|
| Charlson’s comorbidity index |           |              |      |                 |              |      |
| 0                    | 32080(73.22%)   | 6788(61.97%) | 0.242| 27272(62.24%)   | 6788(61.97%) | 0.006|
| 1–2                  | 9937(22.68%)    | 3331(30.41%) | 0.176| 13479(30.76%)   | 3331(30.41%) | 0.008|
| ≥3                   | 1798(4.1%)      | 835(7.62%)   | 0.150| 3065(7.62%)     | 835(7.62%)   | 0.024|
| Comorbidity at baseline |             |              |      |                 |              |      |
| Hypertension         | 3462(7.9%)      | 1077(9.83%)  | 0.068| 3896(8.89%)     | 1077(9.83%)  | 0.032|
| Hyperlipidemia       | 1313(3%)        | 442(4.04%)   | 0.056| 1355(3.09%)     | 442(4.04%)   | 0.051|
| Gout                 | 938(2.14%)      | 323(2.95%)   | 0.051| 1088(2.48%)     | 323(2.95%)   | 0.029|
| Polycystic ovaries   | 1040(2.4%)      | 350(3.2%)    | 0.016| 114(0.26%)      | 350(3.2%)    | 0.011|
| Gestational diabetes | 29(0.07%)       | 19(0.17%)    | 0.031| 47(0.11%)       | 19(0.17%)    | 0.018|
| Depression           | 440(1%)         | 143(1.31%)   | 0.028| 489(1.12%)      | 143(1.31%)   | 0.017|
| Obesity              | 114(0.26%)      | 40(0.37%)    | 0.019| 101(0.23%)      | 40(0.37%)    | 0.025|
| Chronic pancreatitis | 19(0.04%)       | 11(0.1%)     | 0.021| 310(0.07%       | 11(0.1%)     | 0.010|
| Hepatitis B infection| 429(0.98%)      | 189(1.73%)   | 0.065| 693(1.58%)      | 189(1.73%)   | 0.011|
| Hepatitis C infection| 138(0.31%)      | 45(0.41%)    | 0.016| 135(0.31%)      | 45(0.41%)    | 0.017|
| Medication at baseline |             |              |      |                 |              |      |
| Statins              | 559(1.28%)      | 196(1.79%)   | 0.042| 649(1.48%)      | 196(1.79%)   | 0.024|
| Atypical Antipsychotics| 39(0.09%)   | 9(0.08%)     | 0.002| 20(0.05%)       | 9(0.08%)     | 0.014|
| HIV-drug             | 20(0.05%)       | 10(0.09%)    | 0.017| 36(0.08%)       | 10(0.09%)    | 0.003|
| Corticosteroids for systemic | 338(0.77%)   | 189(1.73%)   | 0.086| 648(1.48%)      | 189(1.73%)   | 0.020|
| Immunosuppressants   | 69(0.16%)       | 22(0.2%)     | 0.009| 70(0.16%)       | 22(0.2%)     | 0.010|
| Propensity score     | 2.92±1.4        | 3.33±1.4     | 0.409| 0.02±0.01       | 0.02±0.01    | 0.000|
| Outcome              |                 |              |      |                 |              |      |
| DM                   | 3027(6.91%)     | 811(7.4%)    | 0.019| 2819(6.43%)     | 811(7.4%)    | 0.038|
| death                | 2660(6.07%)     | 705(6.44%)   | 0.015| 2560(5.84%)     | 705(6.44%)   | 0.024|

* Std, standardized difference of greater than 0.1 is considered important imbalance.

https://doi.org/10.1371/journal.pone.0205502.t001
The incidence of type 2 DM stratified by age is shown in Table 3. Here we used the propensity score-based analysis to confirm the hazard ratio of type 2 DM among patients < 30 years of age. The multivariate regression analysis revealed that the aHR of type 2 DM was 2.45 in the appendectomy patients < 20 years (95% CI, 1.039–5.776) compared to controls. The

### Table 2. Incidence and hazard ratios of diabetes mellitus for appendectomy patients compared with non-appendectomy cohort by demographic characteristics and comorbidities.

| Variables | Subjects with non-appendectomy | Subjects with appendectomy | Appendectomy vs. Non-appendectomy cohort | p-value | aHR a (95% CI) | p-value | aHR b (95% CI) | p-value | aHR c (95% CI) | p-value |
|-----------|-------------------------------|-----------------------------|------------------------------------------|---------|----------------|---------|----------------|---------|----------------|---------|
| | N | Event | PY † | incidence ‡ | N | Event | PY † | incidence ‡ | | | |
| All patients | 43815 | 3027 | 340573.93 | 8.89 | (8.57,9.2) | 10954 | 811 | 83432.67 | 9.72 | (9.05,10.39) | 1.091 | (1.01,1.179) | 0.03 | 1.079 | (0.997,1.168) | 0.06 |
| Gender | | | | | | | | | | | | | | | |
| Male | 22372 | 1657 | 170069.30 | 9.74 | (9.27,10.21) | | 5593 | 445 | 41937.96 | 10.61 | (9.63,11.6) | 1.091 | (0.983,1.211) | 0.10 | 1.058 | (0.939,1.192) | 0.34 |
| Female | 21443 | 1370 | 170504.63 | 8.03 | (7.61,8.46) | | 5361 | 366 | 41494.71 | 8.82 | (7.92,9.72) | 1.092 | (0.973,1.225) | 0.13 | 1.072 | (0.964,1.192) | 0.20 |
| Age, years | | | | | | | | | | | | | | | |
| < 30 | 14041 | 179 | 119669.38 | 1.5 | (1.28,1.71) | 3564 | 64 | 29876.48 | 2.14 | (1.62,2.67) | 1.453 | (1.093,1.933) | 0.01 | 1.347 | (1.009,1.798) | 0.04 |
| 30–40 | 10445 | 428 | 83434.68 | 5.13 | (4.64,5.62) | 2599 | 127 | 20565.12 | 6.18 | (5.17,25) | 1.223 | (1.004,1.491) | 0.05 | 1.095 | (0.892,1.344) | 0.39 |
| 40–50 | 8587 | 785 | 66837.74 | 11.74 | (10.92,12.57) | 2114 | 227 | 15941.37 | 14.24 | (12.39,16.09) | 1.197 | (1.033,1.386) | 0.02 | 1.125 | (0.969,1.306) | 0.12 |
| > = 50 | 10742 | 1635 | 70632.14 | 23.15 | (22.03,24.27) | 2677 | 393 | 17049.69 | 23.05 | (20.77,25.33) | 0.981 | (0.879,1.094) | 0.73 | 0.971 | (0.868,1.085) | 0.60 |
| Comorbidity | | | | | | | | | | | | | | | |
| 0 | 38371 | 2183 | 308095.21 | 7.09 | (6.79,7.38) | 9173 | 540 | 72570.45 | 7.44 | (6.81,8.07) | 1.05 | (0.956,1.154) | 0.31 | 1.089 | (0.989,1.2) | 0.08 |
| > = 1 | 5444 | 844 | 32478.72 | 25.99 | (24.23,27.74) | 1781 | 271 | 10862.21 | 24.95 | (21.98,27.92) | 0.966 | (0.844,1.106) | 0.62 | 0.995 | (0.868,1.14) | 0.94 |

†PY, person-years.  
‡Incidence rate, per 1000 person-years.  
Multivariate analysis including age, gender, monthly income, Charlson’s comorbidity index, comorbidities (Hypertension, Hyperlipidemia, Gout, Polycystic ovaries, Gestational diabetes, Depression, Obesity, Chronic pancreatitis, Hepatitis B infection and Hepatitis C infection) and medications (Statins, Atypical Antipsychotics, HIV-drug, Corticosteroids for systemic, Immunosuppressants), where death were regarded as competing risks.  
cHR: crude hazard ratio; aHR: adjusted hazard ratio; CI: confidence interval.  
https://doi.org/10.1371/journal.pone.0205502.t002

The incidence of type 2 DM stratified by age is shown in Table 3. Here we used the propensity score-based analysis to confirm the hazard ratio of type 2 DM among patients < 30 years of age. The multivariate regression analysis revealed that the aHR of type 2 DM was 2.45 in the appendectomy patients < 20 years (95% CI, 1.039–5.776) compared to controls. The

### Table 3. Hazard ratio of incident diabetes mellitus stratified by age.

| Stratify age | aHR a (95% CI) | p-value † | aHR b (95% CI) | p-value ‡ | aHR c (95% CI) | p-value ‡ |
|-------------|----------------|-----------|----------------|-----------|----------------|-----------|
| < 20 | 2.45 (1.039,5.776) | 0.041 | 2.52 (1.116,5.695) | 0.026 | 2.449 (1.085,5.528) | 0.031 |
| < 30 | 1.347 (1.009,1.798) | 0.043 | 1.36 (1.02,1.813) | 0.036 | 1.369 (1.027,1.824) | 0.032 |
| 20–30 | 1.239 (0.907,1.691) | 0.178 | 1.26 (0.924,1.717) | 0.144 | 1.268 (0.931,1.727) | 0.132 |
| 30–40 | 1.071 (0.875,1.31) | 0.509 | 1.144 (0.937,1.397) | 0.188 | 1.147 (0.939,1.401) | 0.178 |

†Adjusted for all variables listed in Table 1.  
‡Adjusted for propensity score.  
*Adjusted for strata by quintiles based on propensity scores.  
‡All analyses incorporated in regard to death as competing risks.  
https://doi.org/10.1371/journal.pone.0205502.t003
propensity score-matching analysis revealed that the aHR of type 2 DM in the appendectomy patients < 20 years was 2.525 (95% CI, 1.116–5.695) compared to controls. The propensity score-based analysis revealed that the aHR of type 2 DM in the appendectomy patients < 30 years was 1.36 (95% CI, 1.02–1.813) compared to controls.

Moreover, the cumulative incidences are shown in Fig 2. The adjusted HR of type 2 DM in all patients with appendectomy was 1.079 (95% CI, 1.041–1.839), that in patients > 30 years of age with appendectomy was 1.002 (95% CI, 0.92–1.09), and that in patients < 30 years of age with appendectomy was 1.36 (95% CI, 1.02–1.813) compared to controls. The incidence of type 2 DM stratified by follow-up period post-appendectomy is shown in Table 4. The incidence of type 2 DM within 3 years post-appendectomy follow-up was higher in the appendectomy patients with an HR of 2.017 (P = 0.03). In contrast, the incidence of type 2 DM > 10

![Cumulative incidence of diabetes mellitus (DM) between the appendectomy and comparison cohorts comparing the cumulative incidence of DM between the appendectomy and comparison cohorts among the overall patients and those patients younger or older than 30 years of age.](https://doi.org/10.1371/journal.pone.0205502.g002)
years post-appendectomy follow-up was lower in the appendectomy group with an HR of 1.442 (P = 0.223).

**Discussion**

In this large retrospective population-based cohort study, we found no statistically significant association between appendectomy and type 2 DM in the overall population (aHR, 1.079; 95% CI, 0.997–1.168). However, appendectomy increased the risk of type 2 DM among patients < 20 years (aHR, 2.45; 95% CI, 1.039–5.776) and those < 30 years (aHR, 1.347; 95% CI, 1.009–1.798). In the random frequency-matched cohort, all confounding factors except Charlson Comorbidity Index score and number of visiting clinics were equally distributed in the appendectomy and control groups. To reduce selection bias, a multivariate regression analysis was conducted of a propensity score-matched cohort, which revealed that the adjusted HR of type 2 DM in the appendectomy patients < 20 years and those < 30 years were 2.52 (95% CI, 1.116–5.695) and 1.36 (95% CI, 1.02–1.813) compared to controls. Since the number of appendectomy patients < 20 years of age was limited, we may have overestimated the impact of age on appendectomy and the development of type 2 DM. Therefore, we concluded that appendectomy prior to 30 years of age is an independent risk factor for the development of type 2 DM.

Apart from significant results in the age subgroup analyses confirmed by the different statistical methods, our results were adjusted by many confounding factors, including hypertension, hyperlipidemia, gout, polycystic ovaries, depression, GDM, depression, obesity, chronic pancreatitis, HBV, HCV, statins, atypical antipsychotics, HIV drugs, corticosteroids, and immunosuppressants. This implies that age indeed had a profound effect on the association between appendectomy and type 2 DM. On the other hand, we found that sex did not influence the association between appendectomy and type 2 DM (P\text{interaction} = 0.88). The aHR of type 2 DM incidence in the male appendectomy group was 1.058 (P = 0.34), while that in the female appendectomy group was 1.072 (P = 0.20) compared to controls. Furthermore, the major outcome was a new diagnosis of DM (ICD-9 250.0–250.9), which included type 1 and 2 DM. Because patients with a history of DM before the index year and subjects < 18 years were excluded, we believe that most of newly diagnosed DM patients after appendectomy have type 2 DM.

Appendicitis is one of the most common acute abdominal diagnoses and mainly results from bacterial infection rather than obstructions within the organ [22]. Appendicitis is a clinical emergency for which surgery remains the gold standard of treatment. Similar to our results, appendectomy is associated with various human diseases [16–21]; however, the mechanism of
their associations is largely unknown. Some possible explanations might address their correlations. First, the appendix is considered a safe house to shelter the commensal intestinal flora through biofilm formation. Second, the appendix is considered part of the immune system because of its abundant gut-associated lymphoid tissue. As a result, appendectomy and prophylactic antibiotics given before appendectomy surgery may disrupt gut microbiota configurations, subsequently supporting diabetes development. Interestingly, several population-based studies from Taiwan were conducted based on the National Health Insurance Research Database (NHIRD) [16, 18–20]. The NHIRD provided the opportunity to investigate the associated with subsequent disease development and appendectomy in real-world settings in a large population sample in Taiwan and can help accumulate evidence for the creation of appropriate surgical interventions to remove the appendix since it might cause long-term health effects.

A recent study revealed that the human appendix accommodates a wealth of microbiota different from other niches and shows substantial diversity [23]. Another study suggested that appendiceal dysbiosis appears in insulin resistance morbidly obese (IR-MO) patients, with a reduction of butyrate-producing bacteria that are necessary to maintain gut integrity together with an increase in mucin-degrading bacteria and opportunistic pathogens [24]. Meadows identified that Firmicutes are associated with weight gain and insulin resistance because they supply extra energy [25]. Verdam et al. described that an increase in Firmicutes and a decrease in Bacteriodetes is linked to the presence of obesity and inflammation [26]. Indeed, the appendiceal microbiota have been recognized as an innovate actor capable of modulating the host metabolism through building the appendiceal immune function [24].

Most importantly, our study showed that appendectomy increases the risk of type 2 DM, particularly when performed in patients before middle age. We believe that dysbiosis or imbalance of the enteric microbiota may bolster chronic inflammation through intestinal barrier breakdown, microbiota outgrowth, and translocation of the microbiota. Moreover, immunity may weaken with age, thereby lessening inflammation. This might address the possibility of the impact of age on appendectomy to the emergence of type 2 DM. Furthermore, other risk factors may attenuate the effect of appendectomy on the development of diabetes after middle age. Appendectomy appeared to be associated with the risk of diabetes development approximately 3–7 years later. We think that changes in the gut microbiota composition could be prominent at the early stage post-appendectomy due to bacterial infection, surgery, and antibiotic use. However, dysbiosis of the enteric microbiota could be recovered by a degree, so animal studies should be performed to clarify the association between appendectomy and type 2 DM.

**Study limitations**

There are some limitations in our study. First, lifestyle data regarding dietary habits, exercise, smoking, socioeconomic status, and hereditary background were not available in this retrospective cohort study. Second, all comorbidities were diagnosed using ICD-9 codes, the accuracy of which should be discussed. Third, we did not separate perforated appendicitis from non-perforated appendicitis or distinguish between laparoscopic appendectomy and open appendectomy. Fourth, despite of our thorough study design and adjustment for confounding factors, some selection bias may have resulted from the retrospective nature of this study.

**Conclusions**

In conclusion, appendectomy performed in patients < 30 years is associated with the risk of type 2 DM independent of hypertension, hyperlipidemia, gout, polycystic ovaries, depression,
GDM, depression, obesity, chronic pancreatitis, HBV, HCV, statins, atypical antipsychotics, HIV drugs, corticosteroids, and immunosuppressants. The results of this study implicate that the appendix protects against type 2 DM development before middle age. Further studies should be performed to clarify the role of appendectomy in the development of diabetes.

Supporting information
S1 Table. Incidence and hazard ratios of diabetes mellitus for appendectomy patients compared with non-appendectomy cohort by demographic characteristics and comorbidities. (DOCX)

Acknowledgments
We thank the Internal Medicine Research Center of Changhua Christian Hospital for supporting our study.

Author Contributions
Formal analysis: Chew-Teng Kor, Diko Zhou, Hsueh-Chou Lai.
Funding acquisition: Wen-Lung Ma.
Investigation: Yang-Ming Lee.
Methodology: Chew-Teng Kor.
Project administration: Yang-Ming Lee.
Software: Chew-Teng Kor.
Supervision: Chia-Chu Chang.
Writing – original draft: Yang-Ming Lee.
Writing – review & editing: Chia-Chu Chang, Wen-Lung Ma.

References
1. Federation ID. in IDF Diabetes Atlas 7th edn http://www.diabetesatlas.org. 2016.
2. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444(7121):860–7. https://doi.org/10.1038/nature05485 PMID: 17167474
3. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. The Journal of clinical investigation. 2005; 115(5):1111–9. https://doi.org/10.1172/JCI25102 PMID: 15864338
4. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444(7122):1022–3. https://doi.org/10.1038/nature05414 PMID: 17183312
5. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444(7122):1027–31. https://doi.org/10.1038/nature05414 PMID: 17183312
6. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(3):979–84. https://doi.org/10.1073/pnas.0605374104 PMID: 17210919
7. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science (New York, NY). 2005; 307(5717):1915–20.
8. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(44):15718–23. https://doi.org/10.1073/pnas.0407076101 PMID: 15505215
9. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57(6):1470–81. https://doi.org/10.2337/db07-1403 PMID: 18305141
10. Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell. 2014; 158(4):705–21. https://doi.org/10.1016/j.cell.2014.05.052 PMID: 25126780

11. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science (New York, NY). 2013; 341(6150):1241214.

12. Randal Bollinger R, Barbas AS, Bush EL, Lin SS, Parker W. Biofilms in the large bowel suggest an apparent function of the human vermiform appendix. Journal of theoretical biology. 2007; 249(4):826–31. https://doi.org/10.1016/j.jtbi.2007.08.032 PMID: 17936308

13. Berry RJ. The True Caecal Apex, or the Vermiform Appendix: Its Minute and Comparative Anatomy. Journal of anatomy and physiology. 1900; 35(Pt 1):83–100.9. PMID: 17232459

14. Spencer J, Finn T, Isaacsong PG. Gut associated lymphoid tissue: a morphological and immunocytochemical study of the human appendix. Gut. 1985; 26(7):672–9. PMID: 3874811

15. Laurin M, Everett ML, Parker W. The cecal appendix: one more immune component with a function disturbed by post-industrial culture. Anatomical record (Hoboken, NJ). 2007; 294(4):567–79.

16. Wu SC, Chen WT, Muo CH, Ke TW, Fang CW, Sung FC. Association between appendectomy and subsequent colorectal cancer development: an Asian population study. PloS one. 2015; 10(2):e0118411. https://doi.org/10.1371/journal.pone.0118411 PMID: 25710790

17. Andersson RE, Olaison G, Tysk C, Ekborn A. Appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology. 2003; 124(1):40–6. https://doi.org/10.1053/gast.2003.50021 PMID: 12512028

18. Liao KF, Lai SW, Lin CL, Chien SH. Appendectomy correlates with increased risk of pyogenic liver abscess: A population-based cohort study in Taiwan. Medicine. 2016; 95(26):e4015. https://doi.org/10.1097/MD.0000000000004015 PMID: 27368018

19. Tzeng YM, Kao LT, Kao S, Lin HC, Tsai MC, Lee CZ. An appendectomy increases the risk of rheumatoid arthritis: a five-year follow-up study. PloS one. 2015; 10(5):e0126816. https://doi.org/10.1371/journal.pone.0126816 PMID: 25970542

20. Lai SW, Lin CL, Liao KF, Tsai SM. Increased risk of pulmonary tuberculosis among patients with appendectomy in Taiwan. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2014; 33(9):1573–7.

21. Sanders NL, Bollinger RR, Lee R, Thomas S, Parker W. Appendectomy and Clostridium difficile colitis: relationships revealed by clinical observations and immunology. World journal of gastroenterology. 2013; 19(34):5607–14. https://doi.org/10.3748/wjg.v19.i34.5607 PMID: 24039352

22. Swidsinski A, Dorfel Y, Loening-Baucke V, Theissig F, Ruckert JC, Ismail M, et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut. 2011; 60(1):34–40. https://doi.org/10.1136/gut.2009.191320 PMID: 19926616

23. Guinane CM, Tadrous A, Fouhy F, Ryan CA, Dempsey EM, Murphy B, et al. Microbial composition of human appendices from patients following appendectomy. mBio. 2013; 4(1).

24. Moreno-Indias I, Sanchez-Alcoholado L, Garcia-Fuentes E, Cardona F, Queipo-Ortuno M, Tinhones FJ. Insulin resistance is associated with specific gut microbiota in appendix samples from morbidly obese patients. American journal of translational research. 2016; 8(12):5672–84. PMID: 28078038

25. Meadows R. Gut bacteria may override genetic protections against diabetes. PLoS biology. 2011; 9(12):e1001215. https://doi.org/10.1371/journal.pbio.1001215 PMID: 22162951

26. Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, et al. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity (Silver Spring, Md). 2013; 21(12):E907–15.